Studies from Cantonal Hospital Have Provided New Information about Antineoplastic Monoclonal Antibodies (Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial)

MLA

“Studies from Cantonal Hospital Have Provided New Information about Antineoplastic Monoclonal Antibodies (Gene Signatures and Expression of MiRNAs Associated with Efficacy of Panitumumab in a Head and Neck Cancer Phase II Trial).” Obesity, Fitness & Wellness Week, July 2018, p. 833. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.547303706&authtype=sso&custid=ns315887.

APA

Studies from Cantonal Hospital Have Provided New Information about Antineoplastic Monoclonal Antibodies (Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial). (2018, July 28). Obesity, Fitness & Wellness Week, 833.

Chicago

Obesity, Fitness & Wellness Week. 2018. “Studies from Cantonal Hospital Have Provided New Information about Antineoplastic Monoclonal Antibodies (Gene Signatures and Expression of MiRNAs Associated with Efficacy of Panitumumab in a Head and Neck Cancer Phase II Trial),” July 28. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.547303706&authtype=sso&custid=ns315887.